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Background: Tumour budding is a histological finding in epithelial cancers indicating an unfavourable phenotype. Previous
studies have demonstrated that it is a negative prognostic indicator in colorectal cancer (CRC), and has been proposed as an
additional factor to incorporate into staging protocols.
Methods: A systematic review of papers until March 2016 published on Embase, Medline, PubMed, PubMed Central and
Cochrane databases pertaining to tumour budding in CRC was performed. Study end points were the presence of lymph node
metastases, recurrence (local and distal) and 5-year cancer-related death.
Results: A total of 7821 patients from 34 papers were included, with a mean rate of tumour budding of 36.8±16.5%. Pooled
analysis suggested that specimens exhibiting tumour budding were significantly associated with lymph node positivity (OR 4.94,
95% CI 3.96–6.17, Po0.00001), more likely to develop disease recurrence over the time period (OR 5.50, 95% CI 3.64–8.29,
Po0.00001) and more likely to lead to cancer-related death at 5 years (OR 4.51, 95% CI 2.55–7.99, Po0.00001).
Conclusions: Tumour budding in CRC is strongly predictive of lymph node metastases, recurrence and cancer-related death at
5 years, and its incorporation into the CRC staging algorithm will contribute to more effective risk stratification.
The TNM staging system for colorectal cancer (CRC) stratifies
patients into stages, which influences their treatment pathway; this
is especially true for rectal cancer where treatment ranges from
local polyp resection to neoadjuvant chemoradiotherapy, surgery
and adjuvant chemotherapy. However, there are many flaws with
this staging system, including the prognostic heterogeneity of
patients with cancers at the same stage (Merkel et al, 2001; Bori
et al, 2009), as well as under- and overtreatment of patient subsets
(Merkel et al, 2001; Nagtegaal et al, 2007; Schiffmann et al, 2013;
Lea et al, 2014; Li et al, 2014a), and no superior method of staging
and prognostication is currently validated (Gao et al, 2012).
The future of CRC care will rely on accurate staging and prognostic
algorithms, potentially with the addition of demographic, bio-
chemical, morphological, molecular and treatment-related para-
meters to improve accuracy. One such parameter for inclusion is
tumour budding, a histological phenomenon in epithelial cancers
when tumour cells or cell clusters migrate into the surrounding
stroma by detaching from the invasive tumour front (Morodomi
et al, 1989; Hase et al, 1993; Ueno et al, 2002b). It represents
de-differentiation of epithelial cells into more invasive phenotypes
in a process known as epithelial–mesenchymal transition (EMT;
Kalluri and Weinberg, 2009).
Tumour budding in CRC has been shown significantly
associated with lymphatic invasion (Morodomi et al, 1989;
Okuyama et al, 2003a, b; Park et al, 2005; Losi et al, 2006; Choi
et al, 2007; Ogawa et al, 2009; Wang et al, 2009), and accordingly
has a well-established association with lymph node metastases, and
is a negative prognostic indicator in terms of recurrence and
overall survival (Ueno et al, 2002a, 2004; Lugli et al, 2009; Wang
et al, 2009; Kevans et al, 2011; Petrelli et al, 2015). An association
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with distant metastases has also been documented (Nakamura
et al, 2005; Suzuki et al, 2009).
Despite this, tumour budding has not been incorporated into
the TNM staging of CRC, partly due to the disagreements in its
definition and identification, with ‘concerns over reproducibility of
assessment, and the wide ranges of percentage of colorectal
tumours reported to show budding in different studies’ (Loughrey
et al, 2014).
One other obstacle when trying to introduce budding in clinical
practice is the fact that some methods for reporting are conceived
for early stages (I–II) and some are for advanced disease (III);
therefore, it is difficult to choose a method suitable for all stages.
The aim of the current study was to perform a systematic review
and meta-analysis of the implications of tumour budding in
operable CRC resection specimens on lymph node metastases,
recurrence and cancer-related death.
MATERIALS AND METHODS
Search protocol. Original studies were searched for those that
documented patients with surgically resected primary colorectal
adenocarcinoma, where the specimens were assessed for the
presence of tumour budding. The outcome measures chosen were
lymph node metastases at resection, rates of recurrence and 5-year
cancer-specific survival rates. Embase, Medline, PubMed, PubMed
Central and Cochrane databases were searched using the following
Boolean search term: budding AND (cancer OR carcinoma
OR adenocarcinoma OR tumor OR tumour) for articles published
up to March 2016. All search results were combined in a reference
manager database (Endnote) and duplicates removed. Reference
lists of included studies were also searched. The inclusion and
exclusion criteria are shown in Figure 1.
Data extraction. Two independent reviewers applied the inclusion
criteria to retrieved study abstracts and selected full papers for data
analysis. These same two reviewers extracted data from full text
papers and applied exclusion criteria in order to identify the final
included studies; discrepancies were verified by consensus.
If multiple publications reported results in the same population,
the most recent report or most comprehensive data were chosen.
For each study, data on baseline characteristics (author institution,
country, study period, total number of patients, sex, site of cancer,
stage, histology, budding definition and methodology) were
extracted. The number of patients exhibiting budding, those with
co-existing lymph node metastases, merged rates of local or distant
recurrence and 5-year cancer-related death rates were obtained
where available. We described outcomes as odds ratios with
95% confidence intervals. Where these were not presented in a
paper, we followed methods described by Parmar to extract them
from Kaplan–Meier curves, or percentage survival. We contacted
authors if data were not presented in a useable form.
Budding definition. There remains to be a consensus on the most
accurate method of assessing tumour budding; currently there are
variations in the cut-off for presence or absence of tumour budding
– some groups use X1 budding focus to define the presence of
tumour budding, whereas other groups use 44 or 49 foci. For
this reason, the defined term was catalogued from each included
paper and displayed in the results. In papers where two methods of
identifying tumour budding were evaluated, the results of the
standard method were used for analysis. For the analysis, budding
was determined to be either present or absent. Where budding was
graded into groups (e.g., mild/moderate/severe), the results for the
mild/moderate groups were combined and compared with the
severe or highest grade group.
Quality analysis. This meta-analysis was conducted in accordance
with the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines. We measured the quality of the
studies on the basis of the Newcastle–Ottawa Scale that assesses the
methodological quality of non-randomised cohort studies for
meta-analysis. The studies were judged by two independent
assessors using a nine-point scale comprising analysis on the
selection of the study group, the comparability of cohorts and the
ascertainment of outcome. Scores above 6 points were taken to
denote studies of high methodological quality.
Statistical analysis. All analyses were conducted with the RevMan
statistical package (Review Manager (RevMan) Version 5.3.
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Heterogeneity between studies for each of
the outcome measures was tested with Cochran’s Q test. The I2
statistic was calculated for an objective measure of heterogeneity.
A fixed-effects meta-analysis was performed in all cases, and where
there was appreciable heterogeneity (I2450% or chi-squared
P-values o0.10) a random-effects model was also used for meta-
analysis. Corresponding funnel plots of Ln standard error as a
function of effect size were used to examine the effect of
publication bias visually, and were statistically tested using Eggers
test. P-values 40.05 were indicative of no publication bias. For
meta-analysis, Mantel–Haenszel odds ratios for lymph node
metastasis, recurrence and 5-year cancer-related death were
extracted and described with 95% confidence intervals. Sensitivity
analysis was performed to identify if any methodological features
were indicative of heterogeneity among studies. Studies were
excluded if they had poor methodological quality (Newcastle–
Ottawa scoreso7), where the definitions of tumour budding were
unclear or not predetermined in the Methods section, or where the
rate of tumour budding in the study was outside of the mean rate
of tumour budding among all studies±1 s.d. from the mean.
Subgroup analysis was also carried out to compare whether tumour
location (colon or rectum), T stage (some studies only included
T1 and T2 tumours) and lymph node status affected results.
RESULTS
Search results. The literature search revealed 2728 publications
(Figure 2). Of the 143 included for full text review, 34 were
Inclusion criteria 
Original publication (reviews, opinions, letters,
protocols and conference proceedings excluded)  
Case–control or cohort studies with > 50
patients
Patients with primary colorectal adenocarcinoma
who underwent primary surgical resection without
prior neoadjuvant therapy or endoscopic resection
Reported histopathological lymph node metastasis
or outcome measures of recurrence or survival 
Exclusion criteria 
Papers in languages other than English 
Papers where data were unavailable or uninterpretable
and authors uncontactable  
Figure 1. Study inclusion and exclusion criteria.
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ultimately included in the meta-analysis (Hase et al, 1993;
Ueno et al, 2002a; Okuyama et al, 2003a, b; Ueno et al, 2004;
Prall et al, 2005; Wang et al, 2005; Yasuda et al, 2007; Kanazawa
et al, 2008; Nakamura et al, 2008; Yamauchi et al, 2008; Lugli et al,
2009; Ogawa et al, 2009; Wang et al, 2009; Homma et al, 2010;
Kajiwara et al, 2010; Komori et al, 2010; Tateishi et al, 2010;
Akishima-Fukasawa et al, 2011; Reggiani Bonetti et al, 2011; Betge
et al, 2012; Nakadoi et al, 2012; Sert Bektas et al, 2012; Zlobec et al,
2012; Wada et al, 2013; Huh et al, 2014; Lai et al, 2014; Nishida
et al, 2014; Ryu et al, 2014; Gilardoni et al, 2015; Macias-Garcia
et al, 2015; Miyachi et al, 2015; Tristante et al, 2015; Barresi et al,
2016). There were a total of 7821 patients included for analysis,
with study groups ranging from 58 to 1114 patients. All studies
were conducted in Europe or Asia. The main characteristics of
eligible studies are characterised in Table 1. Most studies were
retrospective and included patients with colon and rectal cancers
from a mixture of stages. One study included patients with
metastases at diagnosis (Kanazawa et al, 2008); these patients were
excluded for analysis of disease recurrence and so the non-
metastatic data are included here. There were 25 studies that
correlated tumour budding status with lymph node metastases in
the specimen, 12 that examined recurrence rates, and 9 that
documented 5-year cancer-related death rates. The mean rate of
tumour budding was 36.8±16.5%.
Quality of studies. The Newcastle–Ottawa scaling method
assessed the methodological quality of the studies and scores are
outlined in Table 1, with an overview of the scoring system method
in Supplementary Material 1 and raw scores in Supplementary
Material 2. The majority (81.6%) of studies had quality scoresX7,
indicating good methodological quality of included studies, and
four studies (15.6%; Homma et al, 2010; Reggiani Bonetti et al,
2011; Sert Bektas et al, 2012; Lai et al, 2014) had acceptable scores
of 6.
Definitions of tumour budding. There were considerable differ-
ences and an overt lack of standardisation of tumour budding
between studies (Table 2). Twenty-eight studies used standard
haematoxylin and eosin (H&E) staining, four studies used
immunohistochemistry (IHC) and cytokeratin staining (Prall
et al, 2005; Lugli et al, 2009; Ogawa et al, 2009; Zlobec et al,
2012), and two did not specify the technique (Gilardoni et al, 2015;
Macias-Garcia et al, 2015), although one could assume standard
H&E was used. A ‘budding focus’ or its equivalent was defined as
an isolated cancer cell or cluster of less than five cells in 24 studies.
Database search 
2703
Other sources 
25
Abstracts read 
2602 
Non-English papers 100
Duplicate references 26
Not concerning lower intestinal tract
2236 
Regarding methods of tumour budding
analysis or molecular processes
underlying it  98
Not an original study specific to
surgically resected non-metastatic
colorectal cancer without nCRT 111
Included for full text
paper review 
157 
Papers with  50 cases, reports, reviews,
letters and opinions  44
Papers concerning other histological
parameters   37
Included patients with metastases 23 
Patients had neoadjuvant therapy  7
Unable to access paper/uninterpretable
data 
Duplicate data in other papers  5 Included studies 
34 
7
Figure 2. Flow diagram of the systematic review and meta-analysis process.
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The remaining studies were either unclear about the definition of a
budding focus (Yasuda et al, 2007; Kanazawa et al, 2008;
Nakamura et al, 2008) or defined it as an isolated cancer cell or
cluster of less than six cells (Okuyama et al, 2003a; Lugli et al, 2009;
Reggiani Bonetti et al, 2011; Nakadoi et al, 2012; Zlobec et al,
2012), or a cluster of greater than four cancer cells (Okuyama et al,
2003b; Wang et al, 2005). Tumour budding was then defined
according to the number of budding foci in the majority of studies;
there was some heterogeneity with the classifications between
studies. Ten studies identified tumour budding positivity if there
were44 budding foci present in the specimen. Other studies used
49 budding foci (eight studies), X1 focus (five studies), 45 foci
(three studies), 410, 416 or 424 foci (one study each). Three
studies did not quantify the number of budding foci, but graded
tumour budding as mild, moderate or severe, depending on
subjective opinion (Hase et al, 1993) or the proportion of
the tumour margin involved by budding (Kanazawa et al, 2008;
Nakamura et al, 2008). For these studies, the severe group
data were compared with mild and moderate (Kanazawa et al,
2008; Nakamura et al, 2008). One study was unclear as to
the methodology used to determine tumour budding (Homma
et al, 2010).
Meta-analysis results
Lymph node metastasis. There were 25 included studies that
compared the rate of tumour budding to regional lymph
node metastases in the resected specimens, involving 6724
patients. The pooled random-effects analysis suggested that
specimens exhibiting tumour budding were significantly asso-
ciated with lymph node positivity (OR 4.94, 95% CI 3.96–6.17,
Table 1. Overview of included studies
AJCC stage
Author Year Country
Study
period
Site of
cancer
No. of
patients I II III IV
Newcastle–
Ottawa
Score
Hase 1993 Japan 1970–1985 CR 663 | | | 7
Ueno 2002 Japan 1981–1994 R 437 | 7
Okuyama 2003 Japan 1985–1997 C 196 | | 8
Okuyama 2003 Japan 1985–1997 R 83 | | 7
Ueno 2004 Japan 1960–1980 R 1114 | | | 9
Prall 2005 Germany 1994–1999 CR 182 | | 8
Wang 2005 China 1969–2002 CR 159 | | 8
Yasuda 2007 Japan NA CR 86 | | 7
Kanazawa 2008 Japan 1996–2001 CR 133 | | | 7
Nakamura 2008 Japan 1986–1998 C 200 | 7
Yamauchi 2008 Japan 1991–2001 CR 164 | | 8
Lugli 2009 Switzerland 1987–1996 CR 273 | | | 7
Ogawa 2009 Japan 1995–2003 CR 83 | | 8
Wang 2009 Ireland 1990–2004 CR 128 | 9
Homma 2010 Japan 2000–2007 R 65 | | 6
Kajiwara 2010 Japan 1985–2005 CR 244 | | 8
Komori 2010 Japan 1990–2004 CR 111 | | 8
Tateishi 2010 Japan 1992–2005 CR 322 | | 8
Akishima-Fukasawa 2011 Japan 1989–2009 CR 111 | | 7
Reggiani Bonetti 2011 Italy 1989–2004 CR 95 | | 6
Betge 2012 Austria 1984–2005 CR 110 | 8
Nakadoi 2012 Japan 1981–2008 CR 499 | | 8
Sert Bektas 2012 Turkey 2003–2007 CR 73 | | | 6
Wada 2013 Japan 1995–2005 CR 120 | | 8
Zlobec 2012 Switzerland 1987–1996 CR 127 | | | 8
Nishida 2014 Japan 2000–2011 CR 265 | | 8
Huh 2014 Korea 2007–2009 CR 543 | | 8
Lai 2014 China 1999–2007 C 135 | 6
Ryu 2014 Korea 2003–2012 CR 179 | | 8
Gilardoni 2015 Italy 2006–2009 C 196 | | 8
Macias-Garcia 2015 Spain 2000–2011 CR 97 | 8
Tristante 2015 Spain 2011–2014 CR 58 | | 4
Barresi 2016 Italy NA CR 82 | 7
Miyachi 2016 Japan 2001–2014 CR 653 | 7
Abbreviations: C¼ colon only; CR¼ colon and rectum; NA¼ not available; R¼ rectum only.
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Po0.00001; Figure 3). There was moderate heterogeneity
between the studies (I2¼ 53%) and thus a random-effects model
is shown. When sensitivity analysis was performed, omission of
those studies with Newcastle–Ottawa quality scores o7, those
with an unclear definition of tumour budding or those which had
overall rates of tumour budding outside of 1 s.d. of the mean
tumour budding rate did not alter the overall effect of tumour
budding on lymph node metastasis or affect heterogeneity
(OR 4.90, CI 3.90–6.16, I2¼ 55%, OR 5.13, CI 4.02–6.53,
I2¼ 52% and OR 3.98, CI 2.96–5.35, I2¼ 54%, respectively).
Subgroup analysis of studies by tumour location improved
homogeneity; those that included rectal cancer only had an
I2 of 0%, with a fixed-effects model OR remaining significant at
5.36, CI 4.25–6.75. Only one study in this group included
colon cancer only. The remaining studies did not differentiate
between colon and rectal cancers and had an OR for lymph
node metastasis similar to the overall study group (OR 4.83,
CI 3.61–6.45, I2¼ 59%). Fourteen studies only examined lymph
node metastases in T1 and T2 tumours, this group was also
heterogeneous (I2¼ 52%) with an OR of 5.67, CI 3.92–8.21.
Conversely, the 11 studies that did not differentiate between
T stage were also heterogeneous with I2¼ 58% and OR 4.52,
CI 3.39–6.02.
Local or distant recurrence. Twelve studies compared the rate of
tumour budding with local or distant recurrence, involving 2773
patients. The pooled random-effects analysis suggested that
specimens exhibiting tumour budding were significantly more
likely to develop disease recurrence over the time period (OR 5.50,
95% CI 3.64–8.29, Po0.00001; Figure 4). There was moderate
Table 2. Methods of defining tumour budding among included studies
Author Year Staining method Definition of budding focus Tumour budding method
Hase 1993 H&E Cluster of o5 cancer cells Graded into two groups: none/mild or
moderate/severe at invasive front
Ueno 2002 H&E Cluster of o5 cancer cells 45 Budding foci
Okuyama 2002 H&E Cluster of o6 cancer cells X1 Budding focus (Morodomi)
Okuyama 2003 H&E Cluster of 44 cancer cells X1 Budding focus
Ueno 2004 H&E Cluster of o5 cancer cells 49 Budding foci
Prall 2005 Cytokeratin/IHC Cluster of o5 cancer cells 424 Budding foci
Wang 2005 H&E Cluster of 44 cancer cells X1 Budding focus (Morodomi)
Yasuda 2007 H&E Cluster of an unspecified number of cancer cells X1 Budding focus (Hase)
Kanazawa 2008 H&E Cluster of an unspecified number of cancer cells Mild: o1/3 invasive margin
Moderate: 1/3–2/3 invasive margin
Severe: 42/3 invasive margin
Nakamura 2008 H&E Cluster of an unspecified number of cancer cells As per Kanazawa above
Yamauchi 2008 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno modified)
Lugli 2009 Cytokeratin/IHC Cluster of o6 cancer cells 416 Buds per hpf
Ogawa 2009 Cytokeratin/IHC Cluster of o5 cancer cells 49 Budding foci
Wang 2009 H&E Cluster of o5 cancer cells X1 Budding focus
Homma 2010 H&E Cluster of o5 cancer cells Graded none, mild, mod, severe but
did not delineate what comprised each
Kajiwara 2010 H&E Cluster of o5 cancer cells 49 Budding foci
Komori 2010 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno modified)
Tateishi 2010 H&E Cluster of o5 cancer cells X1 Budding focus (Ueno)
Akishima-Fukasawa 2011 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Reggiani Bonetti 2011 H&E Cluster of o6 cancer cells 44 Budding foci (Ueno)
Betge 2012 H&E Cluster of o5 cancer cells 49 Budding foci (Ueno modified)
Nakadoi 2012 H&E Cluster of o6 cancer cells 44 Budding foci (Ueno modified)
Sert Bektas 2012 H&E Cluster of o5 cancer cells 49 Budding foci (Ueno modified)
Wada 2013 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Zlobec 2012 Cytokeratin/IHC Cluster of o6 cancer cells 45 Budding foci
Nishida 2014 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Huh 2014 H&E Cluster of o5 cancer cells 45 Budding foci
Lai 2014 H&E Cluster of o5 cancer cells 49 Budding foci (Ueno modified)
Ryu 2014 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Gilardoni 2014 NS Cluster of o5 cancer cells 44 Budding foci (Ueno)
Macias-Garcia 2014 NS Cluster of o5 cancer cells 410 Budding foci (Ueno modified)
Tristante 2014 NS NS NS
Barresi 2016 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Miyachi 2015 H&E Cluster of o5 cancer cells 44 Budding foci (Ueno)
Abbreviations: H&E¼ haematoxylin and eosin; IHC¼ Immunohistochemistry; NS, not significant.
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heterogeneity between the studies (I2¼ 61%). Sensitivity analysis
with omission of studies of poor methodological quality or those
with unclear definitions of tumour budding did not change the
effect of tumour budding on disease recurrence or affect
heterogeneity results (OR 5.48, CI 3.35–8.97, I2¼ 68% and OR
5.01, CI 2.88–8.73, I2¼ 65%). Exclusion of studies with outlying
rates of overall tumour budding did not improve heterogeneity
with an I2 of 56%, and an OR of 4.54, CI 2.75–7.49. Subgroup
analysis by tumour location could not be performed, as only one
included study focussed on rectal cancer in relation to recurrence.
In the group that examined recurrence in T1/T2 tumours only,
three studies had a heterogeneous I2 of 50%, OR 2.87, CI 1.12–7.35.
The remaining nine studies did not stratify by T stage and
displayed improved homogeneity (I2¼ 42%) and a fixed effects
OR of 7.41, CI 5.77–9.50. In the four studies that only examined
recurrence in node negative resections, the fixed-effects model gave
an OR of 6.57, CI 4.18–10.32, I2¼ 0%. The remaining seven studies
included both node negative and node positive disease, and were
heterogeneous (I2¼ 75%), OR 4.91, CI 2.63–9.17.
Five-year cancer-related death rates. The rate of tumour budding
with 5-year cancer-related death was documented in nine studies,
involving 2234 patients. When analysed using a pooled random-
effects model, the results demonstrate that CRCs with tumour
budding were significantly more likely to lead to cancer-related
death at 5 years (OR 4.51, 95% CI 2.55–7.99, Po0.00001;
Figure 5). There was significant heterogeneity between the studies
(I2¼ 78%) and thus a random-effects model is shown. Sensitivity
analysis excluding studies with Newcastle–Ottawa quality scores
o7 and those with unclearly defined criteria for tumour budding
did not change the overall effect of tumour budding on 5-year
cancer-related death rates or on heterogeneity between studies
(OR 4.39, CI 2.32–8.30, I2¼ 80% and OR 3.58, CI 1.61–7.99,
I2¼ 85%). Including only those studies with rates of tumour
Tumour budding No tumour budding Odds ratio Odds ratio
Study or subgroup
Hase et al (1993)
Huh et al (2014)
Kanazawa et al (2008)
Lai et al (2014)
Nakamura et al (2008)
Nishida et al (2014)
Okuyama et al (2) (2003)
Okuyama et al (2003)
Prall et al (2005)
Reggiani et al (2011)
Total (95% CI)
Total events
Heterogeneity: τ2= 0.29; χ2 = 28.25, df =11 (P = 0.003); I2 = 61%
Test for overall effecta: Z = 8.12 (P < 0.00001)
Gilardoni (2015)
Barresi (2016) 23
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Figure 4. The association of tumour budding with local or distal recurrence in resected colorectal cancer.
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Figure 3. The association of tumour budding with lymph node metastasis in resected colorectal cancer.
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budding within 1 s.d. of the overall mean rate improved I2 to 0%,
with a fixed-effects model OR of 7.43, CI 5.84–9.45. Subgroup
analysis by tumour location included two studies examining
tumour budding with relation to 5-year cancer-related death in
rectal cancer, OR 6.97, CI 5.29–9.19, I2¼ 0%. Three studies
included only colon cancers for analysis, OR 7.71, CI 4.46–13.33,
I2¼ 6%. The remaining four studies did not differentiate between
colon and rectal cancers and were heterogeneous, I2¼ 82%,
OR 2.59, CI 0.85–7.92. Only one study examined 5-year cancer-
related death in those with early (T1/T2) tumours, but when this
was excluded, the remaining studies were homogenous (I2¼ 0%)
with the fixed-effects model giving a significant OR of 6.50,
CI 5.19–8.14. Where node negative tumours only were included,
the four studies were homogenous (I2¼ 0%), with an OR of 5.43,
CI 3.31–8.91, on the fixed-effects model. The remaining studies
included node negative and positive disease and were hetero-
geneous (I2¼ 89%), OR 3.86, CI 1.43–10.41.
Publication bias. Funnel plots were created for each outcome
measure. The shapes of the funnel plots and the statistical tests
revealed no evidence of bias in any of the three groups (P-values
for lymph node metastasis, recurrence and 5-year cancer-related
death were 0.103, 0.402 and 0.363, respectively; Figure 6).
DISCUSSION
The meta-analysis demonstrates that the histopathologic finding of
tumour budding in resected CRC specimens is associated with
concurrent lymph node metastases, disease recurrence and cancer-
related death, despite variations in tumour budding definition
between included studies. Tumour budding appears to indicate an
aggressive phenotype, independent of staging according to the
current TNM guidelines. Personalised patient care is an emerging
concept in the future of cancer treatment (Piccart, 2013; Wazir and
Mokbel, 2014; Jackson and Chester, 2015), and incorporation of
tumour budding into the staging of CRC could assist in tailoring
the management of currently contentious subgroups (Koelzer et al,
2016). Tumour budding may indicate early colorectal tumours
requiring more rigorous treatment approaches, or its absence may
aid decision-making in later stage cancers.
At present there is no proven benefit in treating early stage CRC
patients with chemotherapy (Quasar Collaborative Group et al,
2007; Tournigand et al, 2012); however, we know there are subsets
of stage I and II CRC who have poor prognostic outcomes.
Although the current results suggest that tumour budding
identifies high-risk early stage CRCs, it remains to be determined
whether its presence indicates the need for further treatment in this
subset. Clinical trials stratifying patients according to tumour
budding status may be warranted.
Studies have also looked at tumour budding in other epithelial
cancers, demonstrating a negative prognostic impact in oesopha-
geal (Koike et al, 2008; Brown et al, 2010), breast (Salhia et al,
2015), pancreatic (Karamitopoulou et al, 2013) and lung (Masuda
et al, 2012) carcinomas, but as yet, tumour budding remains a non-
core component of colorectal adenocarcinoma pathologic staging
(Koelzer et al, 2016) and is not formally part of staging of other
cancers. Most studies advocate its identification using standard
pathologic processing methods (H&E, light microscopy), with no
extra staining or pathological processing required – thus this is
potentially a cost-effective addition to current staging protocols.
Cytokeratin staining appears to assist tumour budding detection
and may be worthwhile investigating further (Suzuki et al, 2009;
Puppa et al, 2012). Interestingly, although studies vary in their
definition of how many cells constitute a tumour bud, and how
many buds represent budding, and with considerable inter-
observer variability in its reporting, most studies definitively
demonstrate that the finding is a strong negative prognostic
marker in CRC. A recent systematic review summarises methods of
identifying tumour budding and their relationship to prognosticat-
ing CRC and surmises that despite differences in methodologies
between studies, ‘most methods, if practised with care and some
training, will yield relevant prognostic information as high-degree
tumour budding places a patient at a significant risk for an adverse
outcome’ (van Wyk et al, 2015). However, it is clear that the
definition needs standardisation, and for this, more prospective
trials need to be designed to assess its reproducibility and inter-
observer variation.
As the search herein was performed, other studies have also
supported a negative prognostic role of tumour budding in CRC
(Barresi et al, 2014; Graham et al, 2015). Petrelli et al (2015)
recently undertook a systematic review of tumour budding and its
relation to survival limited to stage II CRC. Their meta-analysis
includes 10 studies and compares favourably with ours in that it
also demonstrates a significantly increased OR for death at 5 years
(OR 6.25, 95% CI 4.04–9.67, Po0.00001).
The results herein strongly demonstrate that tumour budding is
a negative prognostic indicator in almost 7000 patients with CRC –
these results remain robust even with sensitivity and subgroup
analyses. Interestingly, when sensitivity analysis was performed
only to include those studies with a percentage finding of tumour
budding within 1 s.d. above and below the mean for all patients,
the heterogeneity on the studies significantly decreased. This
provides further evidence that standardisation of the definition and
characterisation is imperative in the future of CRC staging.
Staging of CRC using the TNM system is notoriously inaccurate
for prognosticating patient subsets, and thus many other
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Figure 5. The association of tumour budding with 5-year cancer-related death in resected colorectal cancer.
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prognostic markers have been studied. These include circulating
and tumour markers such as cyclin D1 expression, CXCR4, VEGF,
microRNA-21, survivin, CDKN2A hypermethylation, BRAF and
K-ras mutation, as well as the findings of microsatellite instability,
mucinous tumour phenotype and a high neutrophil–lymphocyte
ratio (Guastadisegni et al, 2010; Chen et al, 2012; Safaee Ardekani
et al, 2012; Verhulst et al, 2012; Huang et al, 2013; Xia et al, 2013;
Xing et al, 2013; Lv et al, 2014; Wang et al, 2014; Li et al, 2014b,c;
Rui et al, 2015). Despite the fact that all are negative prognostic
markers for overall survival in CRC, none have pooled hazard or
odds ratios 42 on systematic review. Even more well-established
prognostic indicators such as perineural invasion and high lymph
node ratio are associated with relative risks for poorer overall
survival ofo2.5 (Ceelen et al, 2010; Knijn et al, 2015). The results
of the current study demonstrate that tumour budding has an
effect on survival that is markedly worse than any other previously
studied pathological phenotype, with an OR of 4.5 for cancer-
related death at 5 years in those exhibiting tumour budding. These
findings support its inclusion into CRC pathologic staging as a
marker of a more aggressive disease phenotype.
Early evidence suggests that tumours exhibiting budding do not
respond to neoadjuvant chemotherapy (Bhangu et al, 2014; Rogers
et al, 2014; Sannier et al, 2014). In this study, we excluded rectal
cancers undergoing neoadjuvant chemoradiotherapy (nCRT).
Although this subset of included rectal tumours are likely to be
less advanced, we felt that nCRT inclusion may weaken the data,
and a further meta-analysis of this subset is warranted when more
results are available. It remains to be determined whether tumour
budding should be seen as an indicator for a primary surgical
approach in rectal cancer and foregoing nCRT as these patients are
less likely to respond; more data are required to elucidate this
point. However, those tumours exhibiting budding certainly are
worth considering as a subset to target with adjuvant chemother-
apy in CRC as a whole.
Tumour budding in CRC is strongly predictive of lymph node
metastases, recurrence and cancer-related death at 5 years.
Incorporation of this histological finding into the CRC staging
algorithm is imminent, but will require standardisation of the
pathological description of tumour budding.
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